AllSight
Companies · VSTM · Pharmaceutical Preparations

Verastem, Inc. (VSTM)

Verastem, Inc. (VSTM) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Verastem, Inc. (VSTM) stock — financials & valuation

Key numbers for Verastem, Inc. (VSTM): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 39/100 — a percentile rank of Verastem, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$715.5M
P / S8.2×
EV / EBITDA-4.2×
Gross margin87.0%
Operating margin-182.6%
Net margin-231.6%
Return on equity-405.5%
ROIC3449.6%
Revenue growth3995.7%
Debt / equity1.6×
Dividend yield0.0%

Is Verastem, Inc. overvalued? P/S looks undervalued vs its 5-year range; P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Verastem, Inc.’s own financial statements and shown as context, never as advice.

Aug 6, 2026
Revenue and funding sharply beat expectations, extending runway into late 2027
Aug 6, 2026
Revenue beat, financing extends runway, and VS-7375 data strengthen the pipeline
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact